靶向组织因子的抗体药物偶联物tisotumab vedotin在子宫浆液性癌中的临床前活性
本研究评估了组织因子(TF)在子宫浆液性癌(USC)中的表达,并探讨了靶向TF的抗体药物偶联物tisotumab vedotin(TV)在USC模型中的临床前疗效。结果显示,TF在54%的可评估USC标本中表达,TV对TF表达的USC细胞系和PDX模型具有显著抗肿瘤活性,包括细胞毒作用、旁观者效应和免疫介导杀伤。
要点
- TF在54%的可评估USC标本中通过免疫组化检测到表达。
- TV在TF表达的USC细胞系中显示显著细胞毒性和DNA损伤。
- TV在TF表达的USC PDX模型中显著抑制肿瘤生长并延长生存。
核心结论
- TF在超过一半的可评估USC标本中检测到。
- TV在TF表达的USC细胞系和异种移植模型中表现出强效的临床前抗肿瘤活性。
- 有必要在TF表达的USC患者中开展TV的临床研究。
研究设计与样本
- 临床前研究,使用组织芯片评估154例USC样本的TF表达。
- 使用3例原代USC样本通过流式细胞术和免疫组化评估TF表达。
- 体外评估细胞毒性、DNA损伤、ADCC和旁观者效应,体内使用TF表达的USC PDX模型比较TV与对照。
主要发现
- 免疫组化检测TF表达在79/147(54%)的USC样本中。
- 表达TF的原代USC细胞系对TV的细胞毒性显著高于对照ADC(p < 0.05),dsDNA断裂试验也显示显著差异(p < 0.05)。
- ADCC实验证实TV诱导显著的免疫介导杀伤。
- TV在TF低表达细胞系中直接细胞毒性最小,但在共培养实验中观察到显著的旁观者杀伤(p < 0.05)。
- 在TF表达的USC PDX模型中,TV显著抑制肿瘤生长并延长生存(p < 0.0001)。
临床怎么用
- 对于TF表达的USC患者,TV可能是一种有前景的靶向治疗选择,值得进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer with high recurrence rates and poor survival outcomes. Tissue factor (TF) represents a potentially actionable surface antigen. We evaluated TF expression and the preclinical efficacy of tisotumab vedotin (TV), a TF-targeting antibody drug conjugate (ADC), against USC models. METHODS: A tissue microarray (TMA) was created to evaluate 154 USC samples for TF expression by immunohistochemistry (IHC). TF expression was evaluated in 3 primary USC samples using both flow cytometry and IHC. DNA damage was evaluated via γ-H2AX phosphorylation while cytotoxicity was assessed using flow cytometry-based-assays. Antibody-dependent-cell-mediated-cytotoxicity (ADCC) was measured using 4-h-51Cr-release-assays. Bystander effects were assessed using co-culture systems. In vivo efficacy was evaluated in TF-expressing USC patient derived xenograft (PDX) models comparing TV to controls. RESULTS: TF expression was detected by IHC in 79/147 (54%). Primary USC cell lines expressing TF were significantly more sensitive to TV than Control-ADC in cytotoxicity experiments (p < 0.05) and dsDNA break-assays (p < 0.05). ADCC assays confirmed significant TV- induced immune-mediated killing. TV demonstrated minimal direct cytotoxicity in the TF-low cell lines, however, significant bystander killing was observed in co-culture experiments (p < 0.05). In vivo, TV significantly suppressed tumor growth and prolonged survival in TF expressing USC PDX models (p < 0.0001). CONCLUSIONS: TF was detected in more than half of evaluable USC specimens. TV exhibits potent preclinical anti-tumor activity in TF-expressing USC cell lines and xenografts. Clinical investigations of TV in USC patients with TF expression are warranted.
引用
- Ottum S, Sethi N, Bellone S, et al. Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma. Gynecol Oncol. 2026. PMID: 42456482. doi:10.1016/j.ygyno.2026.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。